EOLS

Evolus (EOLS)

Evolus Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:EOLS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/27	07 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EOLS	Evolus Inc
2024/12/27	07 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EOLS	Evolus Inc
2024/12/14	06 : 05	Business Wire	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:EOLS	Evolus Inc
2024/11/07	07 : 22	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:EOLS	Evolus Inc
2024/11/07	06 : 37	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:EOLS	Evolus Inc
2024/11/07	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EOLS	Evolus Inc
2024/11/07	06 : 05	Business Wire	Evolus Reports Third Quarter 2024 Results	NASDAQ:EOLS	Evolus Inc
2024/11/01	21 : 00	Business Wire	Evolus to Participate in Stifel 2024 Healthcare Conference	NASDAQ:EOLS	Evolus Inc
2024/11/01	03 : 02	Business Wire	Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation	NASDAQ:EOLS	Evolus Inc
2024/10/29	21 : 00	Business Wire	Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers	NASDAQ:EOLS	Evolus Inc
2024/10/23	21 : 00	Business Wire	Evolus to Report Third Quarter Financial Results on November 6, 2024	NASDAQ:EOLS	Evolus Inc
2024/10/12	11 : 53	Business Wire	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:EOLS	Evolus Inc
2024/09/28	10 : 00	Business Wire	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:EOLS	Evolus Inc
2024/09/07	10 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EOLS	Evolus Inc
2024/09/07	10 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EOLS	Evolus Inc
2024/09/06	21 : 00	Business Wire	Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024	NASDAQ:EOLS	Evolus Inc
2024/09/05	05 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EOLS	Evolus Inc
2024/08/10	05 : 30	Business Wire	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:EOLS	Evolus Inc
2024/08/01	06 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:EOLS	Evolus Inc
2024/08/01	05 : 12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EOLS	Evolus Inc
2024/08/01	05 : 05	Business Wire	Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance	NASDAQ:EOLS	Evolus Inc
2024/07/31	21 : 00	Business Wire	Evolus to Hold Investor Day on September 12, 2024	NASDAQ:EOLS	Evolus Inc
2024/07/30	21 : 00	Business Wire	Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia	NASDAQ:EOLS	Evolus Inc
2024/07/25	21 : 00	Business Wire	Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference	NASDAQ:EOLS	Evolus Inc
2024/07/17	21 : 00	Business Wire	Evolus to Report Second Quarter Financial Results on July 31, 2024	NASDAQ:EOLS	Evolus Inc
2024/07/01	21 : 00	Business Wire	Evolus Announces Appointment of Albert G. White III to Board of Directors	NASDAQ:EOLS	Evolus Inc
2024/06/24	21 : 00	Business Wire	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products	NASDAQ:EOLS	Evolus Inc
2024/06/12	21 : 00	Business Wire	Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain	NASDAQ:EOLS	Evolus Inc
2024/06/12	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EOLS	Evolus Inc
2024/06/08	06 : 00	Business Wire	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:EOLS	Evolus Inc